提升腹膜透析病人血色素符合標準比率之改善專案

Improving the Hemoglobin Conformity Rate Among Peritoneal Dialysis Patients

10.3966/172674042016061502004

張簡綉雯(Hsiu-Wen Chang Chein)；闕淑能(Shu-Neng Chueh)；黃小倩(Hsiau-Chien Hwang)

貧血 ； 鐵質缺乏 ； 治療流程 ； 腹膜透析 ； anemia ； iron-deficiency ； treatment protocol ； peritoneal dialysis

臺灣腎臟護理學會雜誌

15卷2期（2016 / 06 / 01）

39 - 52

繁體中文

本專案主要目的為提升腹膜透析病人血色素符合標準比率。本腹膜透析中心統計2012年3月平均血色素僅為8.7 g/dL，病人血色素達美國食品管理局（FDA）建議標準≧10 g/dL以上，僅約佔49.1％。專案小組為提升腹膜透析病人血色素，分析主要原因為：缺乏腹膜透析病人貧血治療流程和鐵劑建議使用規範、鐵劑使用的遵從性低、慢性出血、血中白蛋白質不足、紅血球生成素的作用認知錯誤、未按時注射紅血球生成素。專案小組提出改善方案如下：（1）定期舉辦透析病人改善貧血團體護理指導（2）制訂鐵劑建議使用規範（3）制訂腹膜透析病人貧血治療和轉介流程。方案執行4個月後，腹膜透析病人平均血色素由8.7 g/dL提升至10.2 g/dL，達標準比率佔65.3％，達到本專案目標值10 g/dL以上，顯示本專案有具體成效。

This project aims to improve the percentage of peritoneal dialysis (PD) patients with hemoglobin levels that conform to institutional standards. In our PD center, only 49.1% of patients had hemoglobin levels ≧ 10 g/dL and the average hemoglobin levels was only 8.7 g/dL, which lower than the value of 10 ~ 11 g/dL recommended by the U.S. Food and Drug Administration (FDA). We speculated that the main reasons of low hemoglobin level included iron deficiency, low consumption of high-iron content foods due to a lack of knowledge, chronic bleeding without treatment, and inadequate protein intake. This program therefore sought to improve anemia in PD patients through the following measures: (1) holding regular group education sessions; (2) developing a set of recommendations on iron supplements; (3) development of a treatment protocol for anemia. Four months after the program was implemented, the average hemoglobin levels of our PD patients increased from 8.7 g/dL to 10.2 g/dL, and 65.3% of the PD population reached our original target of 10 g/ dL or higher. In conclusion, this anemia-improving project showed positive and encouraging results, and merits further investigation.

1. Coyer, S. M.,Lash, A. A.(2008).Pathophysiology of anemia and nursing care implications.Medsurg Nursing,17(2),77-83.
2. Food and Drug Administration. (2011, July). Warning: ESAs Increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence.Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103234Orig1s5166_103234Orig1s5266lbl.pdf
3. Hewitt-Taylor, J.(2003).National recommendations and guidelines.Journal of Nursing Management,11(3),158-163.
4. Nation Kidney Foundation(2006).K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease.American Journal of Kidney Diseases,47(5),1-146.
5. Saunders, S.,Mac Leod, M. L.,Salyers, V.,MacMillan, P. D.,Ogborn, M. R.(2013).Anaemia management protocols in the care of haemodialysis patients: examining patient outcomes.Journal of Clinical Nursing,1-10.
6. 方昱偉,張宗興(2009)。鐵劑補充療法於腎性貧血的實證觀點。腎臟與透析，21(2)，123-125。
7. 李文卿,張舜智,黃忠餘,吳明儒(2007)。慢性腎臟病與貧血。腎臟與透析，19(2)，81-88。
8. 林金蘭,謝佩珊,林淑緩,宋美惠,王淑芬(2005)。衛教指導對居家照顧者執行鼻胃管照護之影響。慈濟護理雜誌，4(2)，49-56。
9. 林勤堯,林秉熙(2009)。慢性腎臟病貧血的一般處理原則。腎臟與透析，21(2)，96-99。
10. 洪士元,鍾孝民(2001)。腎性貧血的最新治療趨勢。腎臟與透析，19(3)，134-137。
11. 莊仲華(2007)。腎性貧血鐵劑的使用。腎臟與透析，19(3)，142-144。
12. 莊瑤程,陳靖博,蕭善良,陳建文(2007)。腎性貧血的輔助性療法。腎臟與透析，19(2)，145-151。
13. 曾偉誠,唐德成(2008)。紅血球生成刺激劑於慢性腎臟病之應用。腎臟與透析，20(3)，165-170。
14. 黃志強(2004).血液透析學.台北:合記.
15. 溫武慶,林家義(2005)。鐵相關檢驗於診斷缺鐵性貧血的準確性及效益評估。內科學誌，16，269-273。
16. 廖上智(2007)。腎性貧血之致病機。腎臟與透析，19(3)，107-112。
17. 衛生福利部中央健康保險署（2013）．全民健康保險藥物給付項目及支付標準．取自 http://www.nhi.gov.tw/resource/Webdata/22868_1_全民健康保險藥品給付規定-102 年版（整份帶走）.doc